NEW YORK (GenomeWeb News) – Bayer Healthcare today announced an expansion of its joint research partnership with Tsinghua University in Beijing.
The partnership and its expansion involve the Bayer-Tsinghua Joint Research Center for Innovative Drug Discovery, created in 2009. Bayer and the university have signed a collaborative agreement covering biomedical sciences during the next three years.
Shi Yigong, professor and dean of the School of Life Sciences at Tsinghua University, said that a new focus of the expanded collaboration will be on structural biology. Scientists from the university and Bayer will work together to elucidate the 3-D structure of biological molecular targets for new drug discovery projects.
Since its creation, joint projects at the Bayer-Tsinghua center have honed in on "different research aspects starting from early research programs to gain deeper understanding of disease mechanisms, identification of new drug targets, and spanning further to joint structural biology research and medicinal chemistry programs," Bayer said in a statement.
Bayer also said today that a new endowed chair at the Tsinghua University-Institute of Biomedicine — the first chair in life sciences funded by Bayer in China — will be established with Dong Chen as the first chair.